|
|
Vaccine Detail
|
Anti-HER2/HER3 Dendritic Cell Vaccine |
| Vaccine Information |
- Vaccine Name: Anti-HER2/HER3 Dendritic Cell Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: HER2/HER3 (NCT04348747)
- Immunization Route: Intradermal injection (i.d.)
- Description: The vaccine uses anti-HER2/HER3 dendritic cells in combination with Pembrolizumab in patients with Asymptomatic Brain Metastasis From Triple Negative Breast Cancer (TNBC) or HER2+ Breast Cancer (HER2+BC). The dendritic cells boost the immune system, and the Pembrolizumab enhances cancer immune responses, in combination they may shrink the cancer. (NCT04348747)
|
| Host Response |
|
|
| References |
NCT04348747: Dendritic Cell Vaccines Against Her2/​Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer [https://clinicaltrials.gov/study/NCT04348747]
|
|
